The European Commission has given the thumbs up for Alexza's schizophrenia and bipolar disorder drug Adasuve (loxapine) to be marketed in the EU.
The European Commission has given the thumbs up for Alexza's schizophrenia and bipolar disorder drug Adasuve (loxapine) to be marketed in the EU.
Alexza's partner, Barcelona, Spain-based Grupo Ferrer, will market the drug in the EU, with launch anticipated in the third quarter...
A new small-molecule approach to turning on beneficial genes to counteract disease-causing mutations is being pioneered by Insmed’s UK-based scientists.
The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.
The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.
The company is expecting US FDA approval of the drug in a bigger indication, major depressive disorder, later this year.
